- Organizations: Sight Sciences
Research
24-month data from SAHARA RCT supports TearCare durability for DED
Third set of findings from the long-term study indicates the FDA-cleared system’s ability to deliver “immediate, powerful, repeatable, and long-lasting” dry eye relief.
Products
Sight Sciences debuts OMNI Edge Surgical System
Launching during ASCRS, this new hand-held and single-use MIGS device features the company’s patented, higher-capacity viscoelastic delivery TruSync technology.
Research
Real-world data confirms long-term efficacy of OMNI Surgical System for POAG
Sight Sciences announces 36-month findings demonstrating continued effectiveness of standalone OMNI surgery with either IOP or medication reductions over time.
Legal
Alcon faces penalty over Sight Sciences patent infringement
Jury trial rules that Alcon willfully infringed on three Sight Sciences patents, compelling them to pay $34 million in monetary damages.
Research
Sight Sciences reports real-world data on leading MIGS devices, including OMNI Surgical System
Large-scale, comparative study also evaluated the Hydrus Microstent and iStent inject for lowering IOP in 100,000+ glaucoma patients’ eyes.
Research
SAHARA crossover trial reports significant continued advantages of TearCare for DED
Additional 6-month data supports Sights Sciences’ tech vs Restasis as a primary treatment for addressing the underlying root cause of MGD.
Research
Sight Sciences reports new data from GEMINI extension trial on OMNI Surgical System
Findings build on original 12-month results supporting its efficacy in lowering IOP and medication adherence in OAG.
Products
Sight Sciences, Iridex confirm MACs' withdrawal of final LCDs on MIGS
Proposed changes identified certain glaucoma procedures as investigational and not qualified for Medicare coverage.
Legal
Regeneron wins Eylea patent case
Company sued Viatris over patent infringement of a proposed biosimilar in 2022.
Research
New 2-year MIGS data supports TCOR using the OMNI Surgical System
Real-world study examined the use of three different MIGS devices against cataract surgery alone for treating IOP.
Business
J&J Vision, Sight Sciences add to executive teams
Companies announce the appointment of industry veterans Erin Powers and Matt Link, respectively.
Research
Sight Sciences reports positive 6-month data from trial on TearCare vs Restasis for dry eye
SAHARA trial meets primary endpoint in support of technology, with detailed results to be presented at AAO 2023.
Business
Cigna updates policy to cover canaloplasty and trabeculotomy
The Glaucoma Surgical Procedure policy now includes the FDA-cleared OMNI technology.
Research
Two-year data on OMNI Surgical System shows promise for POAG patients
Results support previous findings for the longest multicenter study on the surgical system for standalone and combination-cataract surgery.
Research
Assessing the significance of the IRIS Registry wide-scale MIGS study
Verana Health Senior Medical Director Michael Mbagwu, MD, dives into implications from this research.
Research
Sight Sciences releases 12-month results from first MIGS analysis of AAO Registry real-world data
First large-scale comparative study assessed procedures in combination with cataract surgery.
Legal
Sight Sciences wins patent lawsuits against Alcon and Ivantis
Company defeats four patent invalidity challenges filed in the United States.
Products
Sight Sciences launches new Ergo-Series for OMNI Surgical System
New features include improved handle ergonomics, removable viscoelastic luer connector, and an updated cannula tip design.
Archives